Phase II Study of XELOX and Cetuximab as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer.

Trial Profile

Phase II Study of XELOX and Cetuximab as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2016

At a glance

  • Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FLEET-2
  • Most Recent Events

    • 01 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 09 Jun 2012 Additional lead investigator(Hideyuki Mishima) identified as reported by University Hospital Medical Information Network - Japan record.
    • 07 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top